CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Trial Parameters
Brief Summary
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Eligibility Criteria
Inclusion Criteria: * Voluntarily sign informed consent form(s) * ≥18 years of age at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A) * Diagnosis of histologically or cytologically confirmed relapsed/refractory (R/R) Non Hodgkins lymphoma as defined as one of the following (Note: only patients with indolent lymphomas that warrant treatment should be treated, this will include those with local symptoms due to progressive/bulky disease, compromised organ function, B symptoms, extra-nodal disease, cytopenias from marrow involvement and/or in the opinion of the treating physician believe that any of the above symptoms or potentially life threatening involvement will occur will be treated): 1. Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a 1\. R/R disease after 2 or more prior lines of systemic therapy 2. Marginal Zone Lymphoma (MZL) nodal of extranodal: 1\. R/R disease after 2 or more prior lin